Hypertrophic cardiomyopathy was long managed with drugs borrowed from other cardiac conditions rather than therapies built for it. Camzyos (mavacamten) changed that as the first cardiac myosin inhibitor approved by the FDA.
By reducing excessive actin-myosin cross-bridging in the heart muscle, it eases outflow tract obstruction and improves exercise capacity rather than only relieving symptoms. The once-daily capsule treats adults with symptomatic NYHA class II-III obstructive hypertrophic cardiomyopathy.
Camzyos is dispensed under a REMS program because of the risk of heart failure from systolic dysfunction, requiring scheduled echocardiographic monitoring. It faces no generic competition and continues to pursue label expansion, making it the benchmark asset as other cardiac myosin inhibitors advance.
